SAR442501

Phase 2Small molecule

Sanofi

SAR442501 is one of 12 small molecule programs targeting Achondroplasia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AchondroplasiaActive, not recruiting

OsteochondrodysplasiaTerminated

AchondroplasiaPhase 2

Active, not recruiting

OsteochondrodysplasiaPhase 2

Terminated

Competition

Competitive Landscape

22 competitors in Achondroplasia

#DrugCompanyPhaseTrials

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Approved

1 2

BMN 333

BioMarin Pharmaceutical

Phase 3

6 3

Voxzogo

BioMarin Pharmaceutical

Phase 2

2 4

Truseltiq

HHelsinn Healthcare SA

Phase 2

1 5

TYRA-300

TTyra Biosciences, Inc

Phase 2

1 6

Yuviwel

Ascendis Pharma

Phase 2

2 7

Recifercept

Pfizer

Phase 2

2 8

SAR442501

Sanofi

Phase 2

2 9

Infigratinib /kg

QQED Therapeutics, a BridgeBio company

Phase 2

2 10

Genotropin

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult1 trial

A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT05846009·76 enrolled

Osteochondrodysplasia1 trial

A Phase 2, Open-label, Multi-center, 2-stage Sequential Cohort, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous SAR442501 in Pediatric Participants With Achondroplasia

Terminated· Sanofi logo

Sanofi·Phase 2·NCT06067425·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SAR442501. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR442501 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR442501. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

SAR442501

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult1 trial

Osteochondrodysplasia1 trial

References

Drug Info

Quick Facts

Related News